The Peng Research Group is committed to investigating the molecular mechanisms driving tumor development and therapy resistance in lung cancer and pleural mesothelioma (PM). Our research centered on identifying and understanding the ‘Achilles heel’ - therapeutically exploitable vulnerabilities - of tumors that have developed intrinsic or acquired resistance to existing treatments. By pinpointing and targeting these critical weaknesses, we aim to develop innovative precision medicine strategies, ultimately offering more effective and personalized therapies for patients with thoracic tumors.
